Anti-CD45 Pretargeted Radioimmunotherapy in a Nonhuman Primate Model.
Damian J. Green(Sylvester Comprehensive Cancer Center), Oliver W. Press(Fred Hutch Cancer Center), Eneida R. Nemecek(Oregon Health & Science University), John M. Pagel(University of Washington), Yukang Lin(Fred Hutch Cancer Center), Anastasia Pantelias(Fred Hutch Cancer Center), Darrell R. Fisher(Richland Community College), Aimee L. Kenoyer(Fred Hutch Cancer Center), Ajay K. Gopal(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Donald K. Hamlin(University of Washington), D. Scott Wilbur(University of Washington)
Cited by 0
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k